|
Market Closed -
Nasdaq
21:00:00 14/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 505.75 USD | -2.07% |
|
+1.95% | +11.56% |
| 08-12 | Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says | MT |
| 08-11 | Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- VRTX Stock
- Consensus Vertex Pharmaceuticals Incorporated
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
